Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Amgen 1Q

Product sales were up 13% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen
 
1Q Revenues: $5.0 billion (+11%)

1Q Earnings: $1.6 billion (+51%)

Comments: Product sales were up 13% driven by Enbrel (+13% to $1.1 billion), Prolia (+39% to $170 million), EPOGEN (+16% to $534 million), Sensipar (+24% to $241 million) and XGEVA (+22% to $245 million). Neulasta/NEUPOGEN sales were flat at $1.1 billion. Unfavorable changes in foreign exchange rates impacted revenue by 2 percentage points. R&D expenses were down 14% to $856 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters